Introduction
Retinol and its derivates participate in a wide range of biological processes and play a significant role in the control of endometrial growth and differentiation. [1] [2] [3] Retinol bioavailability is regulated by the presence of specific cytoplasmic receptors; among these, cellular retinol-binding protein 1 and 2 (CRBP-1 and -2) which are members of the fatty acid-binding protein (FABP) ⁄ CRPB family, have distinct physiological roles. 1, 4 CRBP-1 regulates uptake, subsequent esterification and bioavailability of retinol. 5 Studies based on transcript analysis suggest that endometrium expresses significant levels of CRBP-1 throughout the menstrual cycle, whereas levels of CRBP-2 vary and mediate the effects of ovarian steroids. 6, 7 The recognition of endometrial stromal cells at eutopic and ectopic sites is important for gynaecological pathologists. In fact, endometrial stromal cells show a variable appearance according to hormonal stimuli 8 and may be morphologically confused with myometrial or leiomyomatous cells in uterine curettage specimens. Indeed, morphological overlapping with other mesenchymal-derived cells may make the recognition of ectopic endometrial stromal cells at ectopic sites difficult, but this constitutes an important morphological feature for the diagnosis of endometriosis. Finally, identification of endometrial stromal cells surrounding glands helps to differentiate adenomyosis from minimally invasive, well-differentiated endometrial adenocarcinoma. 8, 9 CD10 has been recently introduced as an immunohistochemical marker of endometrial stroma, 10 although with some limitations. 11, 12 In the present study we investigated the expression of CRBP-1 endometrial stromal cells in normal eutopic sites and in various physiopathological states, and compared it with that of CD10.
Materials and methods

specimens
Tissue samples were obtained from diagnostic biopsy specimens and surgical pathology material over the previous 3 years. Clinical data are reported in Table 1 . Freshly excised samples were formalin-fixed and prepared for histology and immunohistochemistry and in some cases (see Table 1 ) were frozen in isopenthane, previously cooled in liquid nitrogen and stored in pools at )80°C for protein and mRNA extraction (see below).
morphological and immunohistochemical study
Paraffin serial sections (4 lm thick) were stained with haematoxylin and eosin or employed for immunohistochemistry. For the latter, after deparaffinization, blocking of endogenous peroxidase activity with 0.2% H 2 O 2 (20 min) and incubation with normal goat serum (30 min), sections were exposed for 1 h to monoclonal anti-a-smooth muscle actin (a-actin 1 : 100; Dako Cytomation, Glostrup, Denmark), anti-AE1 ⁄ AE3 cytokeratins (1 : 40; Ylem, Avezzano, Italy), anti-CD10 (1 : 10; Ylem) and a polyclonal rabbit anti-CRBP-1 antibody 13 (1 : 100, supplied by G. Gabbiani, Geneva, Switzerland). Before incubation with antibodies, heat-mediated antigen retrieval with a 10-mm sodium citrate buffer solution (pH 6.0) in a microwave oven (three cycles of 5 min) was performed. Diaminobenzidine was used as the final chromogen. All immunohistochemical procedures were performed at room temperature. Semiquantitative CRBP-1 immunoreactivity was estimated at · 200 magnification in at least 10 fields by two of the authors who used the following grading system in arbitrary units: negative (0), weak and focal (0.5) and positive (from 1+ to 3+). The interobserver reproducibility was >95%. For each case, the ratio of the score with the number of fields analysed was calculated.
Results were analysed by means of Student's t-test. The differences were considered statistically significant at a value of P < 0.05.
western blotting
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis was performed as follows. Tissue samples were finely fragmented in the presence of liquid nitrogen and mixed in buffer according to Laemmli, 14 immediately sonicated, boiled for 3 min and centrifuged. Protein content was determined according to the Bradford method 15 and verified by an electrophoretic gel stained with Coomassie Brilliant Blue (R 250; Fluka, Buchs, Switzerland) in methanol, acetic acid and water (45 : 10 : 45). For Western blotting, 16 5-50 lg of proteins were electrophoresed on a 5-20% gradient gel and transferred to nitrocellulose filters (0.45 mm; Schleicher & Schuell, Dassel, Germany). The latter were then incubated with anti-a-actin (1 : 500) or anti-CRBP-1 (1 : 200) followed by a goat anti-mouse and anti-rabbit IgG (1 : 10 5 ), respectively. Enhanced chemiluminescence was used for detection (Amersham Biosciences, Little Chalfont, UK). Quantification of X-Omat R films was performed as previously reported. CRBP-1 and endometrial stroma 513 rna extraction and reverse transcriptionpolymerase chain reaction
Tissue samples were finely homogenized for 60 s using a T25 Ultra-Turrax (Janke & Kunkel, Staufen, Germany) and total RNAs isolated by Tri-Reagent (Molecular Research Centre, Cincinnati, OH, USA), according to the manufacturer's instructions. Each RNA sample was quantified spectrophotometrically at 260 nm. Reverse transcription-polymerase chain reaction (RT-PCR) was performed using specific primers based on a published sequence, as previously reported. 11 PCR products were analysed by electrophoresis on 2.5% agarose gel using 1 lg of pGEM DNA (Promega, Madison, WI, USA) as the marker. The amount of amplified PCR products was analysed by a densitometric reading in triplicate and the final value was expressed as the ratio of each gene amplified to that of b 2 -microglobulin.
11,18
Results
The semiquantitative evaluation of CRBP-1 and CD10 immunostaining of stromal cells is shown in Figure 1 . In general, eutopic endometrial stromal cells were positive for CRBP-1 and negative for a-actin (Figure 2 ). In contrast, underlying myometrial tissue was CRBP-1 negative and a-actin positive, as has been previously reported. 13 CRBP-1 positivity changed during the menstrual cycle (Figure 2 ). CRBP-1 immunoreactivity was present in all stromal cells during the proliferative phase (Figure 2d) . In this phase, CRBP-1 immunoreactivity was less intense than that of CD10 (P < 0.02, Figure 1 ). CRBP-1 expression progressively increased during the secretory phase (Figure 2b,e) . The most marked CRBP-1 immunoreactivity was observed in stromal cells with predecidual changes and in decidua of pregnancy (Figure 2g ). When incubated with CD10, predecidual cells and decidua showed only weak positivity with scattered cells that were more strongly positive (Figure 2h ). This positivity was markedly less than that of CRBP-1 (P < 0.002; Figure 1 ). Stromal cells were still CRBP-1 positive in atrophic endometrium, although the expression was somewhat reduced (Figure 2j ). In atrophic endometrium, CD10 expression was low, focal and mostly periglandular (Figure 2k ). CRBP-1 positivity of stromal cells in adenomyosis (Figure 2a ) was similar to that of endometriosis and comparable to that of eutopic proliferative endometrium. CD10 positivity in endometriosis and adenomyosis was similar to that of proliferative endometrium and somewhat more than that of CRBP-1, although this difference was not significant (Figure 1) . In endometrial polyps, endometrial stromal cells were CRBP-1 positive whereas thick-walled vessels and fibrous stroma were CRBP-1 negative (Figure 2h ). Also in endometrial polyps, CRBP-1 positivity decreased as atrophic changes increased (Figure 2i ). CD10 staining of endometrial polyps was somewhat less than with CRBP-1, although this difference was not significant (Figure 1) . In simple hyperplasia, CRBP-1 and CD10 immunostaining of endometrial stromal cells was similar to that of polyps. In well-differentiated endometrioid carcinoma, stromal CRBP-1 positivity was scarce and less than that of CD10 (P < 0.004). Concerning CRBP-1 immunoreactivity of glands, proliferative and atrophic endometrium showed weak cytoplasmic staining. The latter was also observed in simple endometrial hyperplasia and in well-differentiated endometrioid carcinoma (data not shown).
Densitometric analysis of Western blotting and RT-PCR confirmed the greater CRBP-1 protein and transcript levels in secretory compared with proliferative endometrium and the almost absent expression in myometrial and leiomyomatous tissues (P < 0.01, Figure 3 ). Leiomyomatous tissue and myometrium showed a high a-actin protein and transcript content whereas they were scarce in endometrium, as previously reported. 
Discussion
Our results document that eutopic and ectopic endometrial stromal cells express CRBP-1 in all physiopathological conditions examined. Immunohistochemical and biomolecular data showed that CRBP-1 proteins and transcript levels were higher during the secretory phase compared with those of proliferative endometrium. The highest CRBP-1 immunoreactivity was observed in decidua. CRBP-1 expression was retained in the stroma surrounding adenomyosis and in endometrial stroma of endometriosis and it was similar to that of CD10. In curettage or biopsy specimens or in the absence of endometrial glands, the morphological overlapping between stromal and other mesenchymal cells such as smooth muscle cells (SMCs) and fibroblasts may make their distinction difficult. 8, 9 In particular, SMCs may resemble endometrial stromal cells because of cytoplasmic eosinophilia and the acquisition of round nuclei. This is further complicated by the morphological changes of stromal cells during the menstrual cycle. 8 Conventional and new cytoskeletal markers (a-actin, desmin, and h-caldesmon) have proven to be highly capable of recognizing smooth muscle differentiation in uterine cells. 19, 20 Unfortunately, unlike SMCs, endometrial stromal cells lack a well-characterized immunophenotype. Consequently, the definitive confirmation of eutopic endometrial stromal cells and even more so in the context of adenomyosis and endometriosis is occasionally hindered by the lack of reliable markers for stromal cells. Our results suggest that CRBP-1 immunostaining can help to recognize endometrial stromal cells in the latter conditions.
In recent years, CD10 has been introduced as a marker of endometrial stromal cells. 10, 21 However, CD10 can be also detected in morphologically typical fibroblasts and SMCs 22 and desmin may be found in endometrial stromal cells. 20 Moreover, CD10 positivity has been reported in normal cervical stroma. 11, 12 Thus, CRBP-1 positivity could be a useful marker of cervical endometriosis because, in contrast to CD10, it does not stain cervical stroma. Our results also indicate that CD10 immunostaining is decreased in the stroma of atrophic endometrium and in decidua. In these conditions, CRBP-1 is expressed in the stromal cells.
Presently, the biological role of CRBP-1 in endometrial cells as well as the significance of its variations during the menstrual cycle have not been established. Retinoic acid, the most active retinol derivative, induces a transient increase of CRBP-1 expression in myofibroblasts in vitro, 23 suggesting a link between CRBP-1 and the intracellular conversion of retinol in retinoic acid. In vascular SMCs, high levels of CRBP-1 are associated with increased expression of RAR-a, the receptor that mediates the effects of retinoids at the nuclear level. 24 CRBP-1 expression has been associated with SMC phenotypic differentiation and susceptibility to apoptosis. 25 Expression of CRBP-1 is also an important signal during implantation of the embryo. 26 Moreover, decidual cells, isolated from the uterus and provided with retinol, synthesize and release retinoic acid in the medium. 26 One can thus envisage that CRBP-1 expression could represent a target for pharmacological strategies aimed at influencing endometrial stromal cell growth through the control of retinoic acid bioavailability. Further studies are needed to clarify these points and to evaluate the role of CRBP-1 expression in endometrial glandular cells.
In conclusion, CRBP-1 immunodetection can help in understanding the physiopathological changes which occur in endometrial stroma. In addition, CRBP-1 expression may represent a highly sensitive and diagnostically useful additional marker of endometrial stromal cells in eutopic and ectopic sites. 
